Journal Article Summary
The article investigates the treatment of hyperemesis gravidarum (HG), a severe form of nausea and vomiting during pregnancy, among 1,064 women in Norway from 2002 to 2019. This condition can significantly affect a woman's quality of life and pose serious risks to both maternal and fetal health. The study is particularly relevant as it examines the impact of a 2013 European Medical Agency (EMA) warning regarding the antiemetic metoclopramide, which restricted its use to a maximum of five days, and how this influenced treatment practices and patient outcomes.
The researchers conducted a retrospective review of hospital records for women diagnosed with HG who experienced metabolic disturbances. They analyzed trends in antiemetic use before, during, and after hospitalization, as well as changes in clinical outcomes over time. The findings revealed an overall increase in the use of antiemetics, particularly meclizine, prochlorperazine, and ondansetron, during the study period. However, following the EMA warning, there was a notable 30% decrease in the pre-hospital use of metoclopramide and a 20% drop in the use of any antiemetic prior to hospitalization, which coincided with an earlier admission for treatment and a rise in pregnancy terminations.
Despite the study's strengths, such as its large cohort and detailed treatment data, there are limitations to consider. The findings suggest that the EMA warning may have led to unintended negative consequences, including earlier hospital admissions and an increase in pregnancy terminations. Patients experiencing severe nausea and vomiting during pregnancy should discuss their symptoms and treatment options with their healthcare providers, especially considering the potential risks associated with antiemetic medications and the importance of timely intervention to manage their condition effectively.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Erdal Hilde, Holst Lone, Heitmann Kristine, Trovik Jone. Antiemetic treatment of hyperemesis gravidarum in 1,064 Norwegian women and the impact of European warning on metoclopramide: a retrospective cohort study 2002–2019. BMC Pregnancy and Childbirth 2022. DOI: 10.1186/s12884-022-04777-x. PMID: 35655181. PMCID: PMC9161510.
Featured Pill Pals Product
Metoclopramide 10 mg Tablets --- Generic For Reglan --- TEVA
Metoclopramide 10 mg Tablets — Generic For Reglan — TEVA is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
